Physician
Internal Medicine
Dr. Robert E. Bellet, MD
|
|
Give Review
Doctor Robert E. Bellet, MD is an expert in the field of Internal Medicine. He graduated from Jefferson Medical College. Dr. Robert E. Bellet is a published doctor. He has 41 papers published. The most current publication "Docetaxel in combination with fluorouracil: study design and preliminary results."
Publications
- A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
- Docetaxel in combination with fluorouracil: study design and preliminary results.
- BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.
- Viral hemorrhagic septicemia (VHS) of the rainbow trout bred in France.
- Estrogen-induced hypernephroma.
- Phase I study of ICRF-159 (NSC-129943) in human solid tumors.
- A phase I study of emetine hydrochloride (NSC 33669) in solid tumors.
- Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816).
- Letter: ICRF 159.
- Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).
- Frequency of occult residual melanoma after excision of a clinically positive regional lymph node.
- Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
- Preoperative evaluation of the oncology patient.
- The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
- Protection of central nervous system metastases from systemic chemotherapy by adrenal corticosteroids.
- Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials.
- Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
- Cryptococcal pleural effusion.
- Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
- Multiple primary malignancies in patients with cutaneous melanoma.
- Critical review of previously reported clinical trials of cancer immunotherapy with nonspecific immunostimulants.
- A study of antitumor (phase II) and immunosuppressive effects of ICRF-159 in patients with metastatic melanoma.
- Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea.
- Failure of lymphocyte microcytotoxicity to distinguish relapsers from non-relapsers in melanoma patients receiving post-surgical adjuvant chemotherapy.
- The phase II evaluation of Bacillus Calmette-Guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma.
- ICRF-159: current status and clinical prospects.
- Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
- Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
- Phase II study of ICRF-159 in refractory metastatic breast cancer.
- Phase II trial of VM-26 in patients with metastatic malignant melanoma.
- A Phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma.
- Current concepts of the biology of human cutaneous malignant melanoma.
- Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
- Phase II study of subcutaneously administered 5-azacytidine (NSC-102816) in patients with metastatic malignant melanoma.
- Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
- Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
- Primary choroidal and cutaneous melanomas occurring in a patient with the B-K mole syndrome phenotype.
- Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
- Phase I study of 5-azacytidine (NSC-102816) .
- Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Schools
Thomas Jefferson University
Jefferson Hospital
Albert Einstein Med Center
Doctors Specialties
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Education
-
Thomas Jefferson University -
Albert Einstein Healthcare Network -
Jefferson Medical College
Helpful Reviews
Similar Doctors
|
|
Dr. David E. Rosenthal, MD |